Cookie policy notice

By continuing to use this site you agree to our cookies policy below:
Since 26 May 2011, the law now states that cookies on websites can ony be used with your specific consent. Cookies allow us to ensure that you enjoy the best browsing experience.

This site is intended for health professionals only

At the heart of general practice since 1960

Long-term dual antiplatelet therapy cuts risk of recurrent heart attacks

Patients could benefit from being given dual antiplatelet therapy for up to three years after a heart attack, research suggests.

A US study found patients who were given the antiplatelet ticagrelor on top of standard, low-dose aspirin therapy for three years had a statistically significant reduction in heart disease deaths and complications compared with those on aspirin alone.

Researchers compared ticagrelor – at two different doses, 60mg or 90mg twice daily – with placebo in a study of over 21,000 patients who had recently had a heart attack, all of whom were taking low-dose aspirin.

They found ticagrelor at both doses resulted in around a relative 15% reduction in the risk of cardiovascular death, MI or stroke at three years, compared with placebo. 

However, ticagrelor also significantly increased the risk of major bleeding, from 1.0% to around 2.5% - although the authors said rates of bleeding that led to severe or irreversible harm were less than 1% for all three groups.

Current NICE guidelines recommend dual antiplatelet therapy – with either clopidogel or ticagrelor on top of aspirin – for up to a year post-MI, but whether it is benefits of longer-term dual therapy outweigh the harms remains unclear.

The researchers said their study provides the first ‘prospectively defined evidence affirming the hypothesis that long-term, intensive platelet inhibition… reduces ischaemic events in patients with prior myocardial infarction’.

Given there were fewer discontinuations at the lower ticagrelor dose the team added that the ‘60-mg dose may offer a more attractive benefit-risk profile’.

However, a related editorial pointed out that at this lower dose, treating 10,000 patients for a year would prevent 42 primary endpoint events and cause 31 major bleeding events, a risk-benefit profile described as ‘close to an even proposition’.

NEJM 2015; available online 7 May

Related images

  • pill packs  PPL
  • CQC logo

Readers' comments (1)

  • Vinci Ho

    While we used to treat arterial thrombo-embolic disease as a single entity (at least at the time when I was a medical SHO), it appears we have two trajectories with anti- platelet drugs( probably better in combination)are more for arterial thrombotic diseases and anti- coagulants(old or new) , are more for embolic diseases. Of course , they can co-exist.

    Unsuitable or offensive? Report this comment

Have your say